Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tapinarof - Beijing Wenfeng Tianji Pharmaceuticals/Celestial Pharmaceuticals/Dermavant Sciences/Japan Tobacco/Torii Pharmaceuticals

Next Previous
X
Search
Drug Profile

Tapinarof - Beijing Wenfeng Tianji Pharmaceuticals/Celestial Pharmaceuticals/Dermavant Sciences/Japan Tobacco/Torii Pharmaceuticals

Alternative Names: Benvitimod; DHPS; DMVT 505; GSK-2894512; JTE-061; VTAMA; WBI-1001; Xinbike

Latest Information Update: 19 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Welichem Biotech
  • Developer Beijing Wenfeng Tianji Pharmaceuticals; Dermavant Sciences; Japan Tobacco; Welichem Biotech
  • Class Anti-inflammatories; Antipsoriatics; Nonsteroidal anti-inflammatories; Resorcinols; Skin disorder therapies; Small molecules; Stilbenes
  • Mechanism of Action Aryl hydrocarbon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis; Plaque psoriasis
  • Registered Psoriasis
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 12 Dec 2024 Launched for Atopic dermatitis (In adults, In the elderly, In children, In adolescents) in USA (Topical)
  • 12 Dec 2024 Registered for Atopic dermatitis (In adults, In the elderly, In children, In adolescents) in USA (Topical) - First pediatric approval
  • 05 Nov 2024 FDA assigns PDUFA action date of 12/03/2025 for tapinarof for Atopic dermatitis (In adolescents, In adults, In children, In the elderly) (Topical)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top